Risk of cardiovascular outcomes in subjects with autoantibody testing vs matched control subjects without autoantibody testing.
| Autoantibody | Outcome | Events | Hazard Ratio (95% CI)* |
|---|---|---|---|
| RF | MI, HF, or PVD** | 230 | 1.04 (0.78, 1.37) |
| Death | 264 | 0.95 (0.73, 1.24) | |
| ANA | MI, HF, or PVD** | 215 | 1.20 (0.93, 1.56) |
| Death | 218 | 0.93 (0.73, 1.19) |
↵* Adjusted for age, sex, calendar year, comorbidity, and presence of rheumatic disease.
↵** Defined as first occurrence of any of the 3 events. RF: rheumatoid factor; ANA: antinuclear antibody; MI: myocardial infarction; HF: heart failure; PVD: peripheral vascular disease; HR: hazard ratio; comorbidity: chronic disease comorbidities9.